Greenwich Lifesciences

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

STAFFORD, Texas--( BUSINESS WIRE )--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following year end update.

Greenwich LifeSciences Provides Year End Update

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

After Golden Cross, Greenwich LifeSciences, Inc. (GLSI)'s Technical Outlook is Bright

STAFFORD, Texas--( BUSINESS WIRE )--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to December 31, 2023 which is approximately 39 months from date of the Company's IPO. During this period, current officers, directors and certain shareholders will not be able to sell their shares of the Company's common stock unless otherwise modified by the Board of Directors.

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Aerovate Therapeutics

HeartBeam

Minerva Neurosciences

Virgin Orbit Holdings

Short-squeeze stocks continue to be a big deal for speculative traders and we're helping them out with a list to keep in mind this week! That list comes from Fintel and its Short Squeeze Leaderboard.

GLSI, AVTE: The Top 5 Short Squeeze Stocks to Watch This Week

SurgePays

TOP Ships

Weber

Source: g0d4ather / Shutterstock.com Short squeeze stocks are still popular with speculative traders and that has us going over the top ones to keep an eye on this week! Luckily, Fintel has traders covered with its Short Squeeze Leaderboard.

TOPS, SURG: The Top 5 Short Squeeze Stocks This Week

Blue Apron

TDH Hlds

Syros Pharmaceuticals

Source: g0d4ather / Shutterstock.com Investors are still interested in short squeeze stocks and we've got them covered with the ones to watch this week! Fintel is offering up a list of the short squeeze stocks to watch with its Short Squeeze Leaderboard.

GLSI, APRN: The Top 5 Short Squeeze Stocks to Watch This Week

FaZe Holdings Inc

NeuroBo Pharmaceuticals Inc

Source: Alextype/Shutterstock.com Traders continue to show interest in short squeeze stocks this week as they seek out likely targets to push higher. This has us checking out Fintel's Short Squeeze Leaderboard.

NRBO, FAZE: The Top 5 Short Squeeze Stocks to Watch This Week

Athersys

Singing Machine Co Inc

Source: g0d4ather / Shutterstock.com We're starting off another week with a deep dive into the short squeeze stocks to watch! Short squeeze stocks have been popular with traders in recent months as they search for the next big breakout.

ATHX, PETS: The Top 5 Short Squeeze Stocks to Watch This Week

Greenwich LifeSciences, Inc. is a one-man, one-asset shop. The asset, GP2, has produced excellent breast cancer data.

Greenwich LifeSciences: Persevering CEO And Interesting Data

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

CompoSecure

Chicken Soup for the Soul Entertainment

FAT Brands

Revlon

SNDL Inc.

Toughbuilt Industries Inc

While most people don't like to see red ink in their investment portfolios, at the same time, that negative print comes from volatility — and volatility in either direction presents opportunities for short-term stocks to buy for a quick profit. Here, the narrative isn't necessarily about finding a great company on discount.

7 Short-Term Stocks to Buy for a Quick Profit

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Greenwich Lifesciences Inc (NASDAQ: GLSI) shares are trading higher by 32.95% to $11.46 Tuesday afternoon after the FDA removed the clinical hold on the company's Flamingo-01 Phase 3 trial of GP2. Greenwich Lifesciences says through discussions with the FDA and testing of GP2 in the.

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Greenwich Lifesciences (GLSI) stock is heading higher on Tuesday after the FDA lifted a hold on a Phase III clinical trial. The post Why Is Greenwich Lifesciences (GLSI) Stock Up Today?

Why Is Greenwich Lifesciences (GLSI) Stock Up Today?

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Resume Stock Repurchase Program

Greenwich LifeSciences to Resume Stock Repurchase Program

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Shares of Greenwich LifeSciences, Inc. are trading near their lowest levels since the stock exploded upward in December 2020 in what was an illustrative example of an inefficient market. A still-pending Phase 3 study launch for its only asset in the treatment of breast cancer that was originally expected to initiate in 2020 is primarily to blame.

Greenwich LifeSciences: A First Look

Greenwich LifeSciences is a stock relatively new to the market and lesser-known, as it became public in September of 2020. Not long after, the stock skyrocketed over 1000% on early data that the company's GP2 treatment reduced breast cancer recurrences to zero.

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

AstraZeneca

Biogen

Entera Bio Ltd

GameStop

Longeveron

Riot Blockchain

TRACON Pharmaceuticals

SPDR S&P Biotech ETF

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. The post Recession Fears are Creating a Golden Opportunity for Biotech Stocks appeared first on InvestorPlace.

Recession Fears are Creating a Golden Opportunity for Biotech Stocks

STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

News for Greenwich Lifesciences Stock (GLSI)